Nilotinib (AMN-107)

Catalog No.S1033

Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 210 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Nilotinib (AMN-107) Chemical Structure

Nilotinib (AMN-107) Chemical Structure
Molecular Weight: 529.52

Validation & Quality Control

5 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Bcr-Abl Inhibitors with Unique Features

  • Pan Bcr-Abl Inhibitor

    Imatinib Mesylate (STI571) Multi-target inhibitor of v-Abl, c-Kit and PDGFRIC50=0.6 μM/0.1 μM/0.1 μM.

  • Most Potent Bcr-Abl Inhibitor

    GZD824 Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.

  • FDA-approved Bcr-Abl Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Bcr-Abl Inhibitor

    GZD824 Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Product Information

  • Compare Bcr-Abl Inhibitors
    Compare Bcr-Abl Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
Targets Bcr-Abl [1]
(Murine myeloid progenitor cells)
IC50 <30 nM
In vitro Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7aRnVMUUN3ME2wMlAxODF2NDFOwG0>NGTRfodUSU6JRWK=
KU812NWiyTFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7VOXIxUUN3ME2wMlAxOjR6IN88US=>M1rhTnNCVkeHUh?=
EM-2NV;uOmJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE[wfXBKSzVyPUCuNFA1OSEQvF2=MVfTRW5ITVJ?
LAMA-84NH;3SYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\6ZnJxUUN3ME2wMlAxPDlizszNNUL0OGpqW0GQR1XS
MEG-01MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDsfHNKSzVyPUCuNFA5OjhizszNMVfTRW5ITVJ?
BV-173NVvmdGJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\rXnlPUUN3ME2wMlAyODh7IN88US=>NWDiR2tIW0GQR1XS
KASUMI-1MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrkcmJyUUN3ME2wMlAzPDF|IN88US=>NVzUcW5yW0GQR1XS
NB7MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfK[ZRQUUN3ME2wMlE{PDN7IN88US=>MnHDV2FPT0WU
BHT-101M1\FPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTBwNkSyOlMh|ryPMVrTRW5ITVJ?
CGTH-W-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\NTWM2OD1yLk[0PFch|ryPNVvHVYpuW0GQR1XS
HMV-IINFS0[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnW4TWM2OD1yLke0PFc1KM7:TR?=MW\TRW5ITVJ?
NKM-1NXu2bGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTBwOUCxOUDPxE1?NXrpVo9KW0GQR1XS
LB2241-RCCNVX5[2g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEG4eo5KSzVyPUGuNFIzOjhizszNMWPTRW5ITVJ?
NCI-H1703NVrjN5hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYT2fmZ3UUN3ME2xMlE5QDdizszNMYXTRW5ITVJ?
BE-13NHK2SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX:zRo9PUUN3ME2xMlI4PDF4IN88US=>M{TiO3NCVkeHUh?=
ACNM4\abmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfnUG1LUUN3ME2xMlU2ODd5IN88US=>NVTldJlyW0GQR1XS
A204NGr4e2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrGblBqUUN3ME2xMlU4OjB3IN88US=>M{jUdHNCVkeHUh?=
HOP-62NIS3WINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DIWGlEPTB;MT64NlA4PyEQvF2=NHrBPWtUSU6JRWK=
H9Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTJwN{O3PVMh|ryPMmPqV2FPT0WU
HCC1806MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIr0[5JKSzVyPUKuO|Q{OjdizszNMWjTRW5ITVJ?
NOS-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTD[HV2UUN3ME2yMlg4OTB{IN88US=>MXrTRW5ITVJ?
RS4-11M3nNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPDTWM2OD1{LkmwOlI{KM7:TR?=MYTTRW5ITVJ?
JARNXnEcW15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1P1fmlEPTB;Mj65NlA5PCEQvF2=NVvkdY1kW0GQR1XS
T98GMn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTNwMEGzNVMh|ryPM2O0XXNCVkeHUh?=
NCI-SNU-1M1j4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3mTWM2OD1|LkSwNFkzKM7:TR?=MXfTRW5ITVJ?
SK-MEL-1MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTNwNEOwNlkh|ryPMmK2V2FPT0WU
L-363NWL5SoVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXiZ|h4UUN3ME2zMlYyOTB5IN88US=>MmLNV2FPT0WU
SW982M33QbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTNwNkSxOlkh|ryPMmfiV2FPT0WU
HT-1080M{jFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\mTWM2OD1|LkmxO|c2KM7:TR?=MWDTRW5ITVJ?
G-402MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnaTWM2OD12LkOxNlA{KM7:TR?=NXHwSGZ6W0GQR1XS
HOSM4DleWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrOTWM2OD12LkiwNlgzKM7:TR?=M4T5VHNCVkeHUh?=
SK-NEP-1M{fLdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXX5dnl7UUN3ME20Mlg{OTlzIN88US=>M{Ln[3NCVkeHUh?=
HAL-01MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rn[2lEPTB;ND64PFI1OiEQvF2=MYXTRW5ITVJ?
SBC-1M{C0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTRwOUC5NFch|ryPNV3xOmxlW0GQR1XS
CTV-1NVTyU2ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfnfpFKSzVyPUWuOFg6OzhizszNNVHxdXh[W0GQR1XS
LCLC-103HNIXIfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\qTWM2OD13Lke3OFcyKM7:TR?=MWLTRW5ITVJ?
RVH-421MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTVwN{e1N|Yh|ryPNGH5OWxUSU6JRWK=
K-562MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFzrTY1KSzVyPUWuPVA{PiEQvF2=Mnq2V2FPT0WU
CAL-33M4\nbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\BXplKSzVyPU[uN|E{PTlizszNNF7tZpVUSU6JRWK=
MDA-MB-361MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXO0T|dHUUN3ME22MlM{Pjl7IN88US=>Mn\VV2FPT0WU
IGROV-1MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTZwNEexPVEh|ryPM{LBcXNCVkeHUh?=
NYMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPqTWM2OD14LkWzOVk6KM7:TR?=NXuwfWRXW0GQR1XS
Ramos-2G6-4C10MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUOx[ZhXUUN3ME22MlY3QTNzIN88US=>NYLCPHhqW0GQR1XS
HuO9NIi0doVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILHSVJKSzVyPU[uO|M6PjRizszNM1f4R3NCVkeHUh?=
MS-1NV3ZNYRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvwOmhKSzVyPUeuNVE6PTNizszNNVW2XYgxW0GQR1XS
RPMI-8226MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTdwMkiyPFch|ryPNI\Ob2JUSU6JRWK=
HDLM-2MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\UbGlEPTB;Nz60NFE1QSEQvF2=NHTyPJhUSU6JRWK=
D-566MGNYjRRppET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTGVVZKSzVyPUeuOFcyPTVizszNNIjiOG5USU6JRWK=
SK-MEL-24M4e3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGS4NnRKSzVyPUeuOlM{QTJizszNMVXTRW5ITVJ?
COLO-679MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PXOWlEPTB;Nz65PFY4OSEQvF2=MXvTRW5ITVJ?
EW-13NIDUNZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIDIR2dKSzVyPUiuN|IxPTRizszNM3jKV3NCVkeHUh?=
A388NWnjdVI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vwW2lEPTB;OD6zPFQ5OSEQvF2=MXrTRW5ITVJ?
UM-UC-3MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXzR49KSzVyPUiuOFM6PTZizszNNFHmcZZUSU6JRWK=
NUGC-3Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX33SIk{UUN3ME24MlU{PTh{IN88US=>NGXkRnFUSU6JRWK=
COLO-668MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\xeGlEPTB;OD61PVQ6OSEQvF2=NYTVR|RXW0GQR1XS
MOLT-4NHTKR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDweVlsUUN3ME24MlYzOzV|IN88US=>MlnrV2FPT0WU
D-423MGM2\LfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVruSpY{UUN3ME24Mlg{PzV4IN88US=>NV\lelJxW0GQR1XS
CTB-1MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2O3emlEPTB;OD64O|EzQCEQvF2=NU\xSVlEW0GQR1XS
BCPAPNHr3RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTlwMEK1OlIh|ryPNVfKbnFUW0GQR1XS
GCTM2fQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33vWmlEPTB;OT6wPVg{OSEQvF2=MWXTRW5ITVJ?
ACHNMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFyySIVKSzVyPUmuNlM3OzJizszNM37HSXNCVkeHUh?=
KYSE-520MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHPTWM2OD17LkOzOFgzKM7:TR?=NF7sXWVUSU6JRWK=
LB771-HNCNELHdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3npdWlEPTB;OT63OlQ6PyEQvF2=NVjJb49YW0GQR1XS
MLMAM1HPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIO2V4ZKSzVyPUGwMlAyOzJizszNM2rXdnNCVkeHUh?=
HEC-1M1LSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTFyLkK4NFQh|ryPNWrxbJZzW0GQR1XS
HL-60NUL0bXBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfXWpNbUUN3ME2xNE43QDV|IN88US=>MV3TRW5ITVJ?
A101DNY[wSIU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTFyLki5NlMh|ryPNH31[2dUSU6JRWK=
A2058MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTFyLkmyOFUh|ryPMVrTRW5ITVJ?
KARPAS-45MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2ixfGlEPTB;MUGuNFY{PSEQvF2=NGDsNoZUSU6JRWK=
697M36zfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4WzfmlEPTB;MUGuNlExOSEQvF2=M13pXXNCVkeHUh?=
NCI-N87MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LTSmlEPTB;MUGuO|c{OSEQvF2=MYrTRW5ITVJ?
DSH1Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2G5UGlEPTB;MUGuO|k2OyEQvF2=NIX1fZZUSU6JRWK=
HLEMlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIiwTZhKSzVyPUGxMlg5OzlizszNNEXNXHVUSU6JRWK=
NCI-H720MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXZTWM2OD1zMj62PFAyKM7:TR?=MlSxV2FPT0WU
EW-3NXi4dW9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LLeWlEPTB;MUKuPVMxPyEQvF2=NHzZW4pUSU6JRWK=
AGSMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33TU2lEPTB;MUOuNFM2OSEQvF2=Mlf6V2FPT0WU
ES5M1\G[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DYcGlEPTB;MUOuNFUyOiEQvF2=NFPiV3pUSU6JRWK=
DBNUe2S21YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PFPWlEPTB;MUOuN|I2PiEQvF2=MkHaV2FPT0WU
A4-FukMlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTF|LkSxNFIh|ryPMYfTRW5ITVJ?
A427NUfRcGV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTF|LkS5O|Ih|ryPNV3rcW1GW0GQR1XS
MN-60NGjVXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTF|LkW4OFMh|ryPMWLTRW5ITVJ?
HCC2218M4exfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{KzOmlEPTB;MUOuOVg2PiEQvF2=NGXYOmtUSU6JRWK=
MV-4-11MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTF|LkixN|ch|ryPMlm2V2FPT0WU
GI-1M2e3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWX5bpBSUUN3ME2xOE4yOTh2IN88US=>MVPTRW5ITVJ?
JVM-3MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRTF2LkK2OVYh|ryPMoLFV2FPT0WU
NCI-H2029MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\WTWM2OD1zND6yO|I4KM7:TR?=MnTmV2FPT0WU
TE-12NFrlbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4DiTGlEPTB;MUSuOlA1PiEQvF2=NUCwcVZpW0GQR1XS
WM-115Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmH6TWM2OD1zNT61Olg{KM7:TR?=MWrTRW5ITVJ?
BB65-RCCM{TRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mon3TWM2OD1zNj6wNlQyKM7:TR?=M{jMWHNCVkeHUh?=
NCI-H1693NViyVlQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEHmTHZKSzVyPUG2MlM5ODJizszNM4myenNCVkeHUh?=
KARPAS-299MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnG0TWM2OD1zNj62NlA{KM7:TR?=M1vpfnNCVkeHUh?=
UACC-257NVG5WXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHqVWNKSzVyPUG3MlA2QDJizszNMU\TRW5ITVJ?
RKOMlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmKwTWM2OD1zNz62OFM{KM7:TR?=M{\IeXNCVkeHUh?=
HT-29NULYfGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4C5bGlEPTB;MUeuO|g5QSEQvF2=NVKyUIxRW0GQR1XS
ES7MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHPWJBzUUN3ME2xPE4yOTJ{IN88US=>M3vsOHNCVkeHUh?=
DELMnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHoVY9ZUUN3ME2xPE4{OTd{IN88US=>NYK5NpZsW0GQR1XS
BT-549NGLnVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvjTWM2OD1zOD60NFkzKM7:TR?=M{HhWnNCVkeHUh?=
NCI-H1755NX36PI9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vt[GlEPTB;MUiuOVczOyEQvF2=NUn4WWI1W0GQR1XS
HCE-TNYTOeFlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTF6LkizOFEh|ryPM1L5PXNCVkeHUh?=
LU-139NH\oOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3:4XmlEPTB;MUmuNFQ2QCEQvF2=MkTSV2FPT0WU
ECC10NX\lN4lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4[xeWlEPTB;MUmuNlQ4PSEQvF2=Mn7WV2FPT0WU
769-PMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\vS29KSzVyPUG5MlY{OzVizszNM1XEV3NCVkeHUh?=
BALL-1NIHw[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVWzT2RoUUN3ME2xPU43Pzd3IN88US=>MkS5V2FPT0WU
LXF-289MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\ZXWlEPTB;MUmuPFk4QSEQvF2=NFv1Xm5USU6JRWK=
TYK-nuM{Ho[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTF7LkmzNVUh|ryPNX3k[2l3W0GQR1XS
NCI-H630NEXwOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn:yTWM2OD1zOT65N|c5KM7:TR?=MmLBV2FPT0WU
EW-18M{Hrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\rbIhNUUN3ME2yNE4{QDB{IN88US=>M1KzPHNCVkeHUh?=
KYSE-150M3zhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHPTWM2OD1{MD63NFQ4KM7:TR?=M3j0NXNCVkeHUh?=
LOXIMVIMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TEUGlEPTB;MkCuO|U5PiEQvF2=MWXTRW5ITVJ?
HuP-T3MorZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTUW4Z1UUN3ME2yNU4xQDV{IN88US=>NYq3RZFjW0GQR1XS
MFE-280NWjmWpV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfKTWM2OD1{MT61Olc6KM7:TR?=M4Hpd3NCVkeHUh?=
SK-OV-3NXvZclZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlG1TWM2OD1{MT64OFA5KM7:TR?=M1fFNnNCVkeHUh?=
QIMR-WILMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml62TWM2OD1{Mj6wOFc5KM7:TR?=M4Hv[3NCVkeHUh?=
NCI-H69M1vESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;qTWZyUUN3ME2yNk41Ojl7IN88US=>MmnqV2FPT0WU
TE-5M1\Qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rlSWlEPTB;MkKuOFk3PSEQvF2=MlfGV2FPT0WU
NCI-H1993M1vWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTiTWM2OD1{Mj60PVcyKM7:TR?=NGPxTIlUSU6JRWK=
NCI-H1092MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTJ|LkK4OFMh|ryPMl:5V2FPT0WU
RH-1NIraXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUK4ZmlmUUN3ME2yN{42OzV5IN88US=>NWKzcFZLW0GQR1XS
DBTRG-05MGM2[yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PZdmlEPTB;MkOuPFQ4OiEQvF2=NXHrRpcxW0GQR1XS
Mo-TMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTBTWM2OD1{Mz65JO69VQ>?MmewV2FPT0WU
HD-MY-ZM1Hzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrhTWM2OD1{ND6yN|YzKM7:TR?=NVTTSY9XW0GQR1XS
NCI-H2342NVrDTnVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LuWmlEPTB;MkSuOlc3PyEQvF2=NFvZWVdUSU6JRWK=
C32NUPpOIg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGC4eZpKSzVyPUK0Mlk2PzZizszNM2fpbHNCVkeHUh?=
HTC-C3MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2frfWlEPTB;MkWuN|U4PyEQvF2=M{izZnNCVkeHUh?=
NCI-H358M3fl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYf2eHp{UUN3ME2yOU4{QTR|IN88US=>M372THNCVkeHUh?=
CAL-85-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPSWFZjUUN3ME2yOU41PTd5IN88US=>MWrTRW5ITVJ?
HT-1197MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDiTWM2OD1{NT61N|E6KM7:TR?=MYjTRW5ITVJ?
A172M{Xrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLPTWM2OD1{NT63NVM3KM7:TR?=MWHTRW5ITVJ?
SW1573MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInFfFZKSzVyPUK1Mlc4QDVizszNM1PJUnNCVkeHUh?=
EW-24NYfhbW9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFT6RWhKSzVyPUK1Mlk3OiEQvF2=MV3TRW5ITVJ?
SK-MEL-2NIXvNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHewWldKSzVyPUK2MlA{OTJizszNMX3TRW5ITVJ?
LU-65M1zZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HUWWlEPTB;Mk[uNFQ2OiEQvF2=NVnsO45nW0GQR1XS
KMOE-2NEXzR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjTW3VKSzVyPUK2MlA6OTVizszNNWDpcJVCW0GQR1XS
H-EMC-SSNIewRlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LXXWlEPTB;Mk[uOFEyPCEQvF2=NFTNcoFUSU6JRWK=
H4MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTJ4LkSyOFMh|ryPNWLCbXNCW0GQR1XS
DU-4475M1i0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfIRlhKSzVyPUK3MlE5PzJizszNMXTTRW5ITVJ?
HCT-116M{PEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTJ5LkSzOFkh|ryPNHXrU5hUSU6JRWK=
MSTO-211HM{PBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\Pb2lEPTB;MkeuOlI2PSEQvF2=NH35OY9USU6JRWK=
NCI-H292NXzHN3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1LEWGlEPTB;MkeuPVYyPyEQvF2=MoPTV2FPT0WU
NCI-H446MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTJ6LkKxNFUh|ryPNIfjbGhUSU6JRWK=
NCI-H2009NHWyPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPBfWhwUUN3ME2yPU4yPDNzIN88US=>MnvVV2FPT0WU
MHH-ES-1NXLWXXdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF34[3BKSzVyPUK5MlM3QDVizszNMnzkV2FPT0WU
TI-73NF3GbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7SUVNKSzVyPUK5MlQxODFizszNMX\TRW5ITVJ?
NCI-H2228M2rUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPC[ndRUUN3ME2yPU41PThizszNNFL0boRUSU6JRWK=
MHH-PREB-1M2nue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLJRXdKSzVyPUK5MlU2ODVizszNMoK1V2FPT0WU
ChaGo-K-1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnNeWJKSzVyPUK5MlYxQTdizszNMmfNV2FPT0WU
KY821M4XHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnS[|JKSzVyPUK5MlY1OzNizszNNV;5dXNsW0GQR1XS
NCI-H209MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWD0Um85UUN3ME2yPU45OzZ4IN88US=>MWrTRW5ITVJ?
NBsusSRMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXROYhKSzVyPUK5Mlk6ODRizszNM4ficnNCVkeHUh?=
NCI-H1304MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2mzbWlEPTB;M{CuOVcyPiEQvF2=MWDTRW5ITVJ?
NB14NUn5N3BnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fMNGlEPTB;M{GuNFQ1PiEQvF2=NHfUTpdUSU6JRWK=
HCC1419MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXu1OpRGUUN3ME2zNU4zPCEQvF2=MlPjV2FPT0WU
KG-1MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NESzUHNKSzVyPUOxMlc1OjlizszNM1zZNHNCVkeHUh?=
A2780MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV3JR|UxRTNzLkizOVgh|ryPNF;0eI5USU6JRWK=
NCI-H28NFvHdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1HIUWlEPTB;M{GuPVg3OSEQvF2=NXP6N4JYW0GQR1XS
C2BBe1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTN{LkK2N|Qh|ryPMlj4V2FPT0WU
VA-ES-BJNWXLeJpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTN{LkOxJO69VQ>?NWPBd|FCW0GQR1XS
SBC-5NVLmbGRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7sTWM2OD1|Mj64OVEyKM7:TR?=M3\BWXNCVkeHUh?=
OVCAR-4M13XfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHS5WZBKSzVyPUOzMlQ5PDhizszNNVvuSYlqW0GQR1XS
COR-L88NYHtV2RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH33T49KSzVyPUO0MlA4PDFizszNMWrTRW5ITVJ?
SW954NIDCRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTNOllDUUN3ME2zOE4xPzV{IN88US=>M1vSTHNCVkeHUh?=
COLO-684M3zlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3O0PGlEPTB;M{SuN|QxPCEQvF2=MnXxV2FPT0WU
HCC70MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHOTWM2OD1|ND65OVE1KM7:TR?=MkjhV2FPT0WU
NCI-H1770MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHjTWM2OD1|ND65OlEh|ryPMoPDV2FPT0WU
NCI-H1666MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTN3LkiyOVMh|ryPMnzmV2FPT0WU
YH-13MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PqXWlEPTB;M{WuPVIh|ryPMlTuV2FPT0WU
DJM-1NE[wNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnGU2hRUUN3ME2zOk45ODR7IN88US=>MVzTRW5ITVJ?
KNS-62MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTN4Lkm0N|gh|ryPMXTTRW5ITVJ?
SK-MEL-30NIfjR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUj3eY5uUUN3ME2zO{45PzN5IN88US=>MV3TRW5ITVJ?
SJRH30MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVu5SHRPUUN3ME2zPE44OzRzIN88US=>NXrKdplsW0GQR1XS
GP5dNEjYRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1u2bGlEPTB;M{iuPFY2OyEQvF2=Mn61V2FPT0WU
SW1116M3rtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrocnlUUUN3ME2zPU4zQDB3IN88US=>NFPwdmdUSU6JRWK=
COLO-800NUW5c3U2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml\6TWM2OD1|OT6zOlM5KM7:TR?=MoD0V2FPT0WU
RDNHH1bHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfrdIJKSzVyPUO5MlUzPThizszNNUTlTGY5W0GQR1XS
NCI-SNU-5M4LSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTN7Lk[5NVYh|ryPNV7Y[YlIW0GQR1XS
HuO-3N1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTiTWM2OD12MD6xNFgh|ryPMXXTRW5ITVJ?
SK-UT-1NF;5e49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonqTWM2OD12MD61Olc1KM7:TR?=NVLv[XR{W0GQR1XS
SK-MEL-3MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLoeGg6UUN3ME20NE42QTN{IN88US=>NX\jcYtiW0GQR1XS
SK-MEL-28Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPybIxmUUN3ME20NE43PDN3IN88US=>NXPXZXJZW0GQR1XS
SCC-4MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{DXemlEPTB;NEGuNlE{PyEQvF2=M{fL[3NCVkeHUh?=
no-11MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3Pz[mlEPTB;NEGuO|M2PCEQvF2=Mn\oV2FPT0WU
HT-144NFzme3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTR{LkC1Olch|ryPMU\TRW5ITVJ?
MFM-223MoTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TMRmlEPTB;NEKuOFAzKM7:TR?=M4nJcXNCVkeHUh?=
ONS-76NULSbFRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnzUZBZUUN3ME20Nk45ODF6IN88US=>M2exeHNCVkeHUh?=
ES8M4L1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFn1dWNKSzVyPUSzMlM3QThizszNMUfTRW5ITVJ?
T-24NV\PWlFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;wTWM2OD12Mz60N|Y6KM7:TR?=NHvDblJUSU6JRWK=
GAMGM1f1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTR|LkS1NVch|ryPMkG5V2FPT0WU
LU-135M{LUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvFe4w{UUN3ME20OE4xQTJ|IN88US=>MULTRW5ITVJ?
HCC1187MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjIe2NKSzVyPUS0MlgzPjJizszNM2\Wd3NCVkeHUh?=
TE-1MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzPdlNKSzVyPUS1MlE3PTRizszNM3vMd3NCVkeHUh?=
J-RT3-T3-5NXzTe4dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIe4W45KSzVyPUS1MlQ{OTVizszNMkjpV2FPT0WU
GI-ME-NMoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfG[msxUUN3ME20OU45QTV{IN88US=>MlS3V2FPT0WU
D-392MGMnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnnvTWM2OD12NT65NlU3KM7:TR?=MmTzV2FPT0WU
KALS-1M{\LZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVmz[I44UUN3ME20Ok44OjV5IN88US=>MXrTRW5ITVJ?
MMAC-SFM1H6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXtW4ZKSzVyPUS2Mlk6PTJizszNMoq0V2FPT0WU
HSC-3MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1W4W2lEPTB;NEeuN|YxQCEQvF2=NXXvfGdWW0GQR1XS
KM-H2M3K4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmqyTWM2OD12Nz62NFA4KM7:TR?=NHm2XG5USU6JRWK=
LoVoNWH0fVRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTR6LkGwNFIh|ryPNXO0T4FUW0GQR1XS
NCI-H510ANX7QOYtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUWzW2NyUUN3ME20PE4yQDdzIN88US=>NIHKVlZUSU6JRWK=
EW-11NELrU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTR6LkKzOFgh|ryPNH3KUHFUSU6JRWK=
HCC2998MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPv[3NKSzVyPUS4MlYzOzZizszNMUHTRW5ITVJ?
J82NWe0RmFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2foS2lEPTB;NEiuO|I1OiEQvF2=NXLSd3RzW0GQR1XS
ML-2M13odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHPTWM2OD12OT60OlA2KM7:TR?=NEPicWNUSU6JRWK=
NCI-H2030M1vjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3RTWM2OD12OT63NVE4KM7:TR?=MYXTRW5ITVJ?
NCI-H1792MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTR7Lki1NVgh|ryPMWDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]
Features A selective inhibitor of native and mutant Bcr-Abl.

Protocol(Only for Reference)

Cell Assay: [4]

Cell lines Human primary Schwann and schwannoma cells
Concentrations 1-10 μM
Incubation Time 72 hours
Method Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.

Animal Study: [6]

Animal Models Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
Formulation 10% NMP-90% PEG300, PEG300
Dosages 75 mg/kg, 100 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Weisberg E, et al. Blood. 2007, 109(5), 2112-2120.

[2] Liu Y, et al. J Hepatol. 2011, 55(3), 612-625.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-23)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02709083 Not yet recruiting Chronic Myelogenous Leukemia|Chronic Myeloid Leukemia|Leukemia Emory University December 2016 Phase 2
NCT02774512 Not yet recruiting Colon Cancer Institut Bergonié|Novartis Pharmaceuticals May 2016 Phase 0
NCT02611492 Recruiting Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia Assistance Publique - Hôpitaux de Paris April 2016 Phase 3
NCT02602314 Not yet recruiting Chronyc Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto March 2016 Phase 4
NCT02546674 Recruiting Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis February 2016 Phase 4

view more

Chemical Information

Download Nilotinib (AMN-107) SDF
Molecular Weight (MW) 529.52
Formula

C28H22F3N7O

CAS No. 641571-10-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 27 mg/mL (50.98 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 3mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide

Customer Product Validation(5)


Click to enlarge
Rating
Source FASEB J 2011 25, 3661-3673. Nilotinib (AMN-107) purchased from Selleck
Method Analyzing cell apoptosis
Cell Lines Ba/F3-p210T315I cells
Concentrations 0-5 μM
Incubation Time 24 h
Results In a parallel study using imatinib/PDMP or nilotinib/PDMP combinations, to our surprise, similar significant synergy in Ba/F3-p210T315I cells was observed.

Click to enlarge
Rating
Source Molecules 2014 19, 3356-75. Nilotinib (AMN-107) purchased from Selleck
Method Western blot
Cell Lines K562, CD34+CD38- cells
Concentrations 0, 0.01, 0.1, 1 uM
Incubation Time 12 h
Results Since nilotinib targets the Bcr-Abl kinase in CML cells, we evaluated its ability to inhibit kinase activity in ABCB1- and ABCG2-overexpressing CD34+CD38- cells. In K562 cells, nilotinib effectively inhibited the phosphorylation of Bcr-Abl and CrkL (a surrogate marker of Bcr-Abl activity) at a concentration of 0.1 umol/L. However, in CD34+CD38- cells, nilotinib failed to completely inhibit the phosphorylation of Bcr-Abl and CrkL even when cells were exposed to concentration up to 1.0 umol/L.

Click to enlarge
Rating
Source Leukemia Res 2012 36, 1311-1314. Nilotinib (AMN-107) purchased from Selleck
Method Thymidine uptake Uptake assay
Cell Lines K562, MEG-01 cells
Concentrations 0.1-10uM
Incubation Time 20 min
Results Nilotinib was much more potent than imatinib to inhibit nucleoside transport. It prevented the uptake of thymidine in K562 cells by 97% at 10 uM, a level that was similar to the one obtained with the vasodilatator molecule dipyridamole. Nilotinib was also very efficient at 1 and 0.1 uM; it blocked the entry of thymidine by 90 and 74%, respectively (Fig. 2a). With the MEG-01 cell line, nilotinib was also extremely potent and blocked the entry of thymidine by 96, 92 and 60% with 10, 1 and 0.1 uM nilotinib, respectively (Fig. 2b).

Click to enlarge
Rating
Source Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck
Method Immunoblot analyses
Cell Lines LNCaP, PC-3, DU-145 cells
Concentrations 10 uM
Incubation Time 24 h
Results It shows a robust overexpression of phospho-ERK1/2 T202/Y204 in nilotinib-treated DU-145 cells (B). An up-regulation of phospho-ERK1/2 T202/Y204 was also detectable in nilotinib-treated LNCaP cells, albeit at a lower level, and was not found in PC-3 cells (C).

Click to enlarge
Rating
Source Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck
Method Immunohistochemical staining
Cell Lines Xenografted DU-145 cells
Concentrations 5 mg/kg/d
Incubation Time 21 days
Results Accoding to published animals experiments, DU-145 xenografts from a representative experiment in which nilotinib was used at a 75-mg/kg/d concentration. It's found a significant increase of phospho-ERK-positive residual tumor cells from a mean of 67.5 cells per high-powerfield in controls to 131.1 cells per high-powerfield in DU-145 xenografts treated for 21 days with nilotinib (P< 0.0005).

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcr-Abl Products

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • Imatinib Mesylate (STI571)

    Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

  • Ponatinib (AP24534)

    Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

  • Bafetinib (INNO-406)

    Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

    Features:Dual Bcr-Abl/Lyn inhibitor.

  • Degrasyn (WP1130)

    Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

    Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.

  • DCC-2036 (Rebastinib)

    DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

    Features:A conformational control inhibitor of Abl1 and T315I Abl1.

  • GZD824 Dimesylate

    GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

  • GNF-2

    GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Recently Viewed Items

Tags: buy Nilotinib (AMN-107) | Nilotinib (AMN-107) ic50 | Nilotinib (AMN-107) price | Nilotinib (AMN-107) cost | Nilotinib (AMN-107) solubility dmso | Nilotinib (AMN-107) purchase | Nilotinib (AMN-107) manufacturer | Nilotinib (AMN-107) research buy | Nilotinib (AMN-107) order | Nilotinib (AMN-107) mouse | Nilotinib (AMN-107) chemical structure | Nilotinib (AMN-107) mw | Nilotinib (AMN-107) molecular weight | Nilotinib (AMN-107) datasheet | Nilotinib (AMN-107) supplier | Nilotinib (AMN-107) in vitro | Nilotinib (AMN-107) cell line | Nilotinib (AMN-107) concentration | Nilotinib (AMN-107) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us